JMP Securities raised the firm’s price target on Acadia Pharmaceuticals to $42 from $39 and keeps an Outperform rating on the shares following the Q3 results. The sales performance of NUPLAZID and DAYBUE remains strong as broad clinical development continues to move forward, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD:
- Acadia Pharmaceuticals sees FY23 NUPLAZID net sales $537.5M-$545M
- Acadia Pharmaceuticals sees Q4 DAYBUE net sales $80M-$87.5M
- Acadia Pharmaceuticals reports Q3 EPS (40c), consensus (43c)
- ACAD Earnings this Week: How Will it Perform?
- Acadia Pharmaceuticals initiated with a Buy at UBS
Questions or Comments about the article? Write to editor@tipranks.com